Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Frovatriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B known ✓ | P28222 | 3/20 | 1.00 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 0.86 |
| ▸ | DRD4 | P21917 | 1/20 | 0.86 |
| ▸ | HTR1E | P28566 | 1/20 | 0.86 |
| ▸ | HTR7 | P34969 | 1/20 | 0.86 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.86 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
| ▸ | HTR1F | P30939 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Frovatriptan SCHEMBL29360449 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Frovatriptan SCHEMBL16365906 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Frovatriptan SCHEMBL2456983 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Frovatriptan SCHEMBL3474278 | 0.99 | HTR1B (0.98) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Frovatriptan SCHEMBL672784 | 0.94 | HTR1B (0.98) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Frovatriptan SCHEMBL5489168 | 0.94 | HTR1B (0.98) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Frovatriptan SCHEMBL2321442 | 0.93 | HTR1B (1.00) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| SCHEMBL7030069 | 0.89 | HTR1B (0.80) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| SCHEMBL8018884 | 0.87 | HTR1A (0.78) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| SCHEMBL8018888 | 0.87 | HTR1A (0.78) | HTR1BHTR1AHTR1DDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8716 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| EP-4740962-A1 | PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION | Shanghai WD Pharmaceutical Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| EP-4734974-A1 | CANNABINOID COMPOSITION FOR USE IN THE TREATMENT OF PAIN AND/OR INFLAMMATION | Mabewo Phytopharm AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090164-A1 | COMPOSITIONS COMPRISING ELISMETREP AND A SECOND THERAPEUTIC AGENT FOR TREATING OR PREVENTING MIGRAINE OR PAIN | KALLYOPE, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4698530-A1 | NK3 MODULATORS AND USES THEREOF | Kallyope, Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | MORNINGSIDE VENTURE INVESTMENTS LTD (MC) | 2026-01-29 | — | — | US | claimed |
| EP-4681714-A2 | METHODS OF TREATING THE SYMPTOMS OF AUTISM SPECTRUM DISORDER | MapLight Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | claimed |
| US-12515030-B2 | Transdermal drug delivery devices and methods | MORNINGSIDE VENTURE INVESTMENTS LIMITED (MC) | 2026-01-06 | — | — | US | claimed |
| US-20260001942-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H LUNDBECK AS (DK) | 2026-01-01 | — | — | US | claimed |
| WO-2025262247-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H. LUNDBECK A/S (DK) | 2025-12-26 | — | — | WO | claimed |
| EP-1100499-A1 | PREVENTION OF MIGRAINE RECURRENCE | Pfizer Limited (GB) | 2001-05-23 | — | — | EP | claimed |
| WO-2001028555-A1 | EMULSION COMPOSITIONS FOR POLYFUNCTIONAL ACTIVE INGREDIENTS | LIPOCINE, INC. (US) | 2001-04-26 | — | — | WO | claimed |
| EP-1083918-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE 5-HT RECEPTORS | Advanced Medicine, Inc. (US) | 2001-03-21 | — | — | EP | claimed |
| WO-2001015677-A2 | USE OF 5-HT1B/1D AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| WO-2000066115-A1 | DEVICE AND METHOD FOR PROPHYLAXIS OF MIGRAINE | GLAXO GROUP LIMITED (GB) | 2000-11-09 | — | — | WO | claimed |
| WO-2000059475-A1 | COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF IONIZABLE HYDROPHOBIC THERAPEUTIC AGENTS | LIPOCINE, INC. (US) | 2000-10-12 | — | — | WO | claimed |
| WO-2000050007-A1 | COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF HYDROPHOBIC THERAPEUTIC AGENTS | LIPOCINE, INC. (US) | 2000-08-31 | — | — | WO | claimed |
| US-6060499-A | Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs | POZEN, INC. (US) | 2000-05-09 | — | — | US | claimed |
| WO-2000006161-A1 | PREVENTION OF MIGRAINE RECURRENCE | PFIZER LIMITED (GB) | 2000-02-10 | — | — | WO | claimed |
| WO-1999064044-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE 5-HT RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |